12 Best Small Cap Pharma Stocks to Buy Now

Page 4 of 10

7. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Number of Hedge Fund Holders: 27

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a biopharmaceutical company based in London, UK, dedicated to discovering, acquiring, developing, and commercializing treatments for patients with serious diseases that have unmet medical needs.

The emphasis Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) placed on raising prescriber adoption and disease awareness showed encouraging Q3 2024 results. The fact that over 2,550 prescribers have written Arcalyst prescriptions for recurrent pericarditis since the medication’s debut in April 2021 serves as proof of this. The average total length of Arcalyst therapy for recurrent pericarditis increased to almost 27 months by the end of Q3 2024. The focus continues to be on Kiniksa Pharmaceuticals International, plc’s (NASDAQ:KNSA) clinical pipeline, which includes the continuing abiprubart studies for Sjögren’s disease.

Notably, Arcalyst’s rise among new and returning prescribers was sustained by continuous execution across the commercial organization, which includes deliberate investments in brand and illness awareness.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) anticipates that Arcalyst’s net sales will reach $410–$420 million by 2024. The business has been recruiting and administering medication to participants in the Phase 2b clinical trial of Abiprubart for Sjögren’s disease. It anticipates maintaining a positive cash flow each year while investing in all aspects of its operations, including pipeline development and commercialization.

Industry experts claim that commercial initiatives and disease awareness efforts have been driving up prescriber adoption. With a focus on raising illness awareness and recurrent pericarditis diagnosis, Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) anticipates sustained growth in Arcalyst sales and prescriber numbers, strengthening its position among the best pharmaceutical stocks. The business is still concentrating on investing to introduce novel therapies for crippling illnesses to the market.

Page 4 of 10